Core Viewpoint - The announcement by Xinyi International regarding the capital increase agreement aims to enhance the production capabilities of its subsidiary, Xinyi Optoelectronics, and its joint venture, Xinyi (Renshou) High-end Display Technology Co., Ltd. [1] Group 1: Capital Increase Agreement - Xinyi Optoelectronics and Xinyi Renshou have signed a capital increase agreement, with a total investment of 840 million RMB, where Xinyi Optoelectronics contributes 500 million RMB and Xinyi Renshou contributes 340 million RMB [1]. - Following the capital increase, Xinyi International's indirect shareholding in Xinyi Renshou will decrease from 100% to 60% [4]. Group 2: Business Focus - Xinyi International's main business includes the manufacturing and sales of liquid crystal display products, touch screen products, and electronic consumer products such as micro camera modules and fingerprint recognition modules [4]. - Xinyi Optoelectronics specializes in touch screen and micro camera module businesses, while Xinyi Renshou focuses on the manufacturing and sales of touch screen products [4].

Core Viewpoint - The announcement by Xinyi International regarding the capital increase of its indirect wholly-owned subsidiary, Xinyi Optoelectronics, and its joint venture company, Xinyi Renshou, indicates a strategic move to inject a total of 840 million RMB into Guangdian Renshou, reducing Xinyi International's indirect stake from 100% to 60% [1][11]. Group 1: Capital Increase Details - The capital increase agreement involves three parties: Xinyi Optoelectronics, Guangdian Renshou, and Xinyi Renshou [5][15]. - Xinyi Optoelectronics will contribute 500 million RMB, while Xinyi Renshou will contribute 340 million RMB, totaling 840 million RMB [5][15]. - The payment for the capital increase will be settled in cash, and the funds must be paid within 180 days from the signing of the agreement [9][19]. Group 2: Changes in Ownership Structure - Following the capital increase, Guangdian Renshou's registered capital will rise from 10 million RMB to 850 million RMB, significantly altering the ownership structure [9][19]. - Xinyi Optoelectronics' shareholding will decrease to 60%, while Xinyi Renshou will acquire a 40% stake through its investment [9][19]. Group 3: Purpose and Business Context - The primary purpose of the capital increase is to provide necessary funding support for Guangdian Renshou's display component and module production line project [9][19]. - Guangdian Renshou specializes in the manufacturing and sales of touchscreen products, while Xinyi Renshou, as a joint venture of Xinyi International, focuses on liquid crystal display products, aiming to integrate resources in the display industry [9][19]. Group 4: Financial Performance of Guangdian Renshou - Guangdian Renshou has been operating at a loss, with a pre-tax loss of 221 million RMB and a post-tax loss of 228 million RMB as of December 31, 2023, resulting in a net asset value of -154 million RMB [10][20]. - For the year 2024, the pre-tax and post-tax losses are projected to be 92.45 million RMB, with net assets further declining to -246 million RMB [10][20]. - Despite the reduction in ownership percentage, Xinyi International will maintain control over Guangdian Renshou, which will continue to be included in the consolidated financial statements of the group [10][20].

Group 1 - The company, Ultrasonic Electronics, confirmed that its printed circuit board and LCD products are applied in the medical field and are currently supplying normally [2] - There is an inquiry from investors regarding the company's involvement in smart healthcare and AR medical applications, indicating interest in the company's product offerings in these areas [2] - The company has not specified any actual orders related to smart healthcare or AR medical applications in the response [2]

Core Viewpoint - The company, Ultrasonic Electronics (000823.SZ), confirmed that its printed circuit board and liquid crystal display products are being utilized in the medical field and are currently being supplied normally [1]. Group 1 - The company has applications for its printed circuit board products in the medical sector [1]. - The liquid crystal display products of the company are also used in medical applications [1]. - Supply of both product lines is reported to be normal [1].